FDA describes agency’s initiatives to accommodate growth in cell and gene therapy fields
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy